Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02339454
Other study ID # ESMR-RCT-UP
Secondary ID
Status Completed
Phase Phase 3
First received January 12, 2015
Last updated April 7, 2018
Start date May 2012
Est. completion date December 2017

Study information

Verified date April 2018
Source Moscow State University of Medicine and Dentistry
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Low intensity shockwaves have been proven in animal and pilot clinical studies to induce local growth of new blood vessels. Small single-center clinical trials with shockwave therapy showed promising results in reducing angina symptoms, improving perfusion and contractility in patients with refractory angina and stress-induced ischemia on imaging test.

The hypothesis of this study is that shockwave therapy could improve angina symptoms and exercise tolerance in broader population of patients with stable angina regardless of imaging test results Study aims to demonstrate anti-anginal efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy (ESMR), on top of stable optimal medical treatment in patients with stable angina.


Description:

Low intensity shockwaves (0.09 millijoule/mm2) are delivered to myocardial tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave (ECG) to avoid arrhythmias. The treatment is painless.

At first, the patient undergoes modified Bruce treadmill test, to assess exercise induced ischemia.

Exercise induced ECG ischemia is defined as the new development of horizontal or down - sloping ST segment depression (≥1 mm at 60 ms after J point) versus baseline tracing.

Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.

During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

The spots are localized by the ultra-sound device and the shockwaves are focused to this area. Several treatments are required for optimal results.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female patients (females of childbearing potential must be using adequate contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomized partner).

- Patients aged = 18 years.

- Patients with coronary artery disease confirmed by angiography, prior MI, prior revascularization (PCI, CABG) and with exercise angina not controlled by the optimal medical therapy.

- Patient should be on a stable dosage of medication used to treat angina for at least 4 weeks prior to enrollment.

- ST-segment depression = 1mm during exercise ECG.

- Able and willing to sign informed consent and to comply with study procedures.

- Written informed consent prior to enrolment into the study.

Exclusion Criteria:

- Angina at rest.

- ECG abnormalities at rest (left bundle-branch block, resting ST-segment depression = 1mm, digoxin therapy, WPW-syndrome).

- Planned coronary intervention or CABG within 6 months.

- Heart failure (class III or IV NYHA).

- Moderate-severe hypertension (SBP>160 mmHg and/or DBP>100 mmHg).

- Hypotension (SBP<100 mmHg).

- Acute coronary syndrome or coronary revascularization procedure within the prior 3 months before enrolment.

- Females who are pregnant or nursing.

- Any clinically relevant hematological or biochemical abnormality on routine screening, according to Investigator's judgment.

- Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).

- Renal impairment defined as Creatinine >150 mcmol/l.

- Mild, moderate or severe hepatic impairment or hepatic insufficiency defined as: SGOT or SGPT > 3 times greater than normal upper limit or total serum bilirubin > 1.5 times greater than normal upper limit

- Existing contraindications for exercise testing (e.g. acute myocarditis or pericarditis, DVT, severe aortic stenosis)

- Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicines, drugs or psychoactive substances.

- Conditions which in the Investigator's opinion may interfere with the study's execution or due to which the patient should not participate for safety reasons.

- Risk of low patient cooperation.

- Inability or unwillingness to issue the informed consent.

- Patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any cardiac shock wave therapy machine of a competitor company within 3 months of entry into the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Active treatment group
Energy Density - 0.09 mJ/mm2 Device: Active Applicator
Placebo group
Placebo Applicator

Locations

Country Name City State
Lithuania Vilnius University Hospital, Santariskiu klinkos Vilnius
Russian Federation Moscow state university of medicine&dentistry Moscow

Sponsors (3)

Lead Sponsor Collaborator
Evgeny Shkolnik, MD Medispec, Vilnius University

Countries where clinical trial is conducted

Lithuania,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Total Exercise duration To evaluate if ESMR able to improve total exercise duration in modified Bruce treadmill test.
Patients will be assessed at baseline visit (screening) and 6 months after the first treatment.
6 months
Secondary Time to 1 mm ST-segment depression in modified Bruce treadmill test 6 months
Secondary Time to angina in modified Bruce treadmill test 6 months
Secondary Number of angina attacks per week 6 months
Secondary Number of sublingual nitroglycerin consumption per week 6 months
Secondary CCS angina functional class 6 months
Secondary Seattle angina questionnaire score 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT01257282 - Prevalence and Prognostic Value of Unrecognized Myocardial Injury in Stable Coronary Artery Disease (PUMI) N/A
Completed NCT02294942 - Extended-Release RANCAD in the Patients With Stable Angina Pectoris Phase 3
Completed NCT02029118 - Acupoint Application in Patients With Stable Angina Pectoris (AASAP) Early Phase 1
Completed NCT00763464 - Coronary Artery Disease (CAD) in Postmenopausal Women N/A
Recruiting NCT02328898 - Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent Phase 4
Completed NCT01502943 - Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Phase 4
Terminated NCT00638326 - Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity Phase 3
Withdrawn NCT02165670 - BASIC VALIDATE Coronary Stent Registry
Completed NCT01632371 - Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 Phase 4
Completed NCT01363661 - Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris Phase 4
Completed NCT01293097 - Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI Phase 4
Completed NCT02747329 - A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT N/A
Recruiting NCT05347069 - Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization Phase 4
Recruiting NCT04938661 - Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE) N/A
Not yet recruiting NCT03155971 - PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial) N/A
Active, not recruiting NCT02285322 - Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study N/A
Active, not recruiting NCT02062021 - Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease N/A
Active, not recruiting NCT01947361 - Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber) N/A
Active, not recruiting NCT01937065 - Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study N/A
Completed NCT01669382 - Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites Phase 3